top of page

Second Xencor - Janssen Bispecific Antibody Collaboration

Sexton Riley LLP represented Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, in its October 2021 collaboration agreement with Xencor, Inc. to develop and commercialize novel B-cell targeting bispecific antibodies that are designed to conditionally activate T cells through the CD28 co-stimulatory receptor.

bottom of page